211 related articles for article (PubMed ID: 34312290)
21. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
[TBL] [Abstract][Full Text] [Related]
22. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.
Ferrans VJ; Yu ZX; Nelson WK; Valencia JC; Tatsuguchi A; Avila NA; Riemenschn W; Matsui K; Travis WD; Moss J
J Nippon Med Sch; 2000 Oct; 67(5):311-29. PubMed ID: 11031360
[TBL] [Abstract][Full Text] [Related]
23. Human Pluripotent Stem Cell-Derived
Julian LM; Delaney SP; Wang Y; Goldberg AA; Doré C; Yockell-Lelièvre J; Tam RY; Giannikou K; McMurray F; Shoichet MS; Harper ME; Henske EP; Kwiatkowski DJ; Darling TN; Moss J; Kristof AS; Stanford WL
Cancer Res; 2017 Oct; 77(20):5491-5502. PubMed ID: 28830860
[TBL] [Abstract][Full Text] [Related]
24. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
Kristof AS; You Z; Han YS; Giaid A
Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
26. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
27. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
[TBL] [Abstract][Full Text] [Related]
28. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
[TBL] [Abstract][Full Text] [Related]
29. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
[TBL] [Abstract][Full Text] [Related]
30. Spindle cell lesion on fine needle aspiration as an initial step for diagnosis of lymphangioleiomyomatosis: Report of a rare case.
Manukyan I; Sidawy M; DeBrito P
Diagn Cytopathol; 2021 Sep; 49(9):E352-E355. PubMed ID: 34000096
[TBL] [Abstract][Full Text] [Related]
31. Lymphatic manifestations of lymphangioleiomyomatosis.
Gupta R; Kitaichi M; Inoue Y; Kotloff R; McCormack FX
Lymphology; 2014 Sep; 47(3):106-17. PubMed ID: 25420303
[TBL] [Abstract][Full Text] [Related]
32. Risk of breast cancer in patients with lymphangioleiomyomatosis.
Nuñez O; Baldi BG; Radzikowska E; Carvalho CRR; Herranz C; Sobiecka M; Torre O; Harari S; Vergeer MAMH; Kolbe J; Pollán M; Pujana MA
Cancer Epidemiol; 2019 Aug; 61():154-156. PubMed ID: 31260937
[TBL] [Abstract][Full Text] [Related]
33. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.
Matsumoto Y; Horiba K; Usuki J; Chu SC; Ferrans VJ; Moss J
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):327-36. PubMed ID: 10460750
[TBL] [Abstract][Full Text] [Related]
34. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
35. Study of breast cancer incidence in patients of lymphangioleiomyomatosis.
Nuñez O; Román A; Johnson SR; Inoue Y; Hirose M; Casanova Á; de Garibay GR; Herranz C; Bueno-Moreno G; Boni J; Mateo F; Petit A; Climent F; Soler T; Vidal A; Sánchez-Mut JV; Esteller M; López JI; García N; Gumà A; Ortega R; Plà MJ; Campos M; Ansótegui E; Molina-Molina M; Valenzuela C; Ussetti P; Laporta R; Ancochea J; Xaubet A; Pollán M; Pujana MA
Breast Cancer Res Treat; 2016 Feb; 156(1):195-201. PubMed ID: 26951504
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
39. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.
Fujita A; Ando K; Kobayashi E; Mitani K; Okudera K; Nakashima M; Miyatake S; Tsurusaki Y; Saitsu H; Seyama K; Miyake N; Matsumoto N
Hum Genet; 2016 Jan; 135(1):61-8. PubMed ID: 26563443
[TBL] [Abstract][Full Text] [Related]
40. Emerging biomarkers of lymphangioleiomyomatosis.
Nijmeh J; El-Chemaly S; Henske EP
Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
